This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Cerliponase alfa parenteral


Infusions of cerliponase alfa.

Drugs List

  • BRINEURA 150mg/5ml solution for infusion
  • cerliponase alfa 150mg/5ml solution for infusion
  • Therapeutic Indications


    Neuronal ceroid lipofuscinosis type 2


    A flushing solution should be administered after the infusion is complete.


    Children aged 2 years and older
    300mg once every other week.

    Children aged 1 to under 2 years
    200mg once every other week for the first 4 doses and then 300mg once every other week for subsequent doses.

    Children aged 6 months to under 1 year
    150mg once every other week.

    Children under 6 months
    100mg once every other week.

    Additional Dosage Information

    Dose adjustment may be necessary in patients who cannot tolerate the infusion. The dose may be reduced by 50% and/or the infusion rate decreased to a slower rate.

    If the infusion is stopped because of hypersensitivity reactions, it should be restarted at approximately one half the initial infusion rate at which the hypersensitivity reaction occurred.

    The infusion should be interrupted and/or the rate slowed in patients who the treating physician believes may have a possible increase in intracranial pressure as suggested by symptoms such as headache, nausea, vomiting, or decreased mental state. These precautions are of particular importance in patients below 3 years of age.


    For intracerebroventricular infusion only.

    The infusion rate for cerliponase alfa and the flushing solution is 2.5ml per hour.


    Administration site infection
    Ventriculo-peritoneal shunt

    Precautions and Warnings

    Children under 2 years
    Cardiac conduction defects
    Obstructive hydrocephalus
    Structural cardiac disorder

    Pre-medicate with antihistamines with or without antipyretics
    Treatment to be initiated and supervised by a specialist
    Aseptic technique should be used throughout
    For single use only
    Resuscitation facilities must be immediately available
    Perform ECG before and during treatment
    During long term use make clinical examinations at regular intervals
    Monitor cerebrospinal fluid for signs of infection
    Monitor for increased intracranial pressure regularly
    Monitor for intracerebroventricular access device complications
    Monitor patient for infusion-associated reactions (IARs)
    Monitor vital signs, respiration & cardiac function
    Interrupt therapy/reduce infusion rate if infusion-related reactions occur
    Discontinue if serious allergic or anaphylactic reaction occurs
    Consider interrupting treatment if infection occurs

    Infusion related reactions can be minimised by pre-treatment with antihistamines and/or antipyretics from 30 to 60 minutes prior to infusion.

    The scalp should be inspected for skin integrity and to detect intracerebroventricular access device leakage and/or failure prior to the start of the infusion.

    Limited data is available for children aged 2 years and no clinical data is available in children less than 2 years of age. The safety and efficacy in children less than 3 years has not yet been established. There is limited data in patients aged over 8 years.

    Electrocardiogram (ECG) monitoring should be performed during the infusion in patients with a history of bradycardia, conduction disorders, or with structural heart disease, as some patients with neuronal lipofuscinosis type 2 disease may develop conduction disorders or heart disease. In patients with no previous cardiac problems, an ECG should be performed every 6 months.

    Continuation of long term treatment with cerliponase alfa should be subject to regular clinical evaluation, and on whether the benefits outweigh the potential risks to individual patients.

    Pregnancy and Lactation


    Use cerliponase alfa with caution during pregnancy.

    The manufacturer recommends that cerliponase alfa should only be given to pregnant women if clearly needed. Animal studies have not been carried out using cerliponase alfa. At the time of writing, there is limited data on the use of cerliponase alfa during human pregnancy. Potential risks are unknown.


    Cerliponase alfa is contraindicated during breastfeeding.

    The manufacturer recommends that the patient should stop breastfeeding when cerliponase alfa is used. At the time of writing, there is limited data regarding the use of cerliponase alfa during breastfeeding. Effects on exposed infants are unknown.

    Side Effects

    Abdominal pain
    Cerebrospinal fluid pleocytosis
    Cerebrospinal fluid protein abnormalities
    Complications associated with the administration device
    Dropped head syndrome
    ECG changes
    Gastrointestinal disorder
    Hypersensitivity reactions
    Local infection at injection site
    Oral mucosal blistering
    Tongue blistering
    Upper respiratory tract infection


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: February 2020

    Reference Sources

    Summary of Product Characteristics: Brineura 150mg solution for infusion. Biomarin International Limited. Revised May 2017.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.